Novo Nordisk AS (NVO) reports significant sales and profit growth, driven by obesity care expansion and strategic ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Novo Nordisk (NVO) offered investors an update about ongoing cost-cutting efforts as copycat weight-loss drugs weigh on sales ...

While Novo Nordisk has gotten a lot of attention for its obesity/weight-loss drug Wegovy in recent years, Novo Nordisk is ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 ...

Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Sales of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro in India doubled in July, according to Pharmarack data. Wegovy, ...

The news comes days after Novo cut its full-year outlook due to rising competition from copycat compounders, and named a new ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.